Nineteen patients with stage III & IV nonsmali cell lung cancer were treated with regimen containing pacUtaxel and carboplatin at Dharmais National Cancer Center Hospital and Pertamina General Hospital, Jakarta-Indonesia. There were 14 males and 5 females, the histologic diagnosis being adenocarcinoma in 13 patients, squamous carcinoma in 5 patients and adenosquanwus carcinoma in I patient. Fourteen patients were in stage IV, 4 had stage IIIB, one had stage IIIA disease. The regimen contains pacUtaxel 135-200 mg/m2, combined with carboplatin 300 mg/m2 orAUC 6 mg/ml. min, given every 3 weeks. Those who underwent at least 3 cycles of chemotherapy were followed up until death. Objective improvement (partial response) was seen in 12 patients or 63%; 2 had stable disease (11%) and 5 had progressive disease (26%). Two patients are still alive at 22 months and 23 months after starting chemotherapy. The one year survival rate was 58% and median survival time was 14 months.
- Nonsmall cell carcinoma